Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > HORIBA Medical and CEA-Leti Strengthen Their Partnership to Develop Tomorrow’s Diagnostics at the Point of Care

Abstract:
HORIBA Medical, a subsidiary of Japan-based HORIBA Group, the global leader for measurement and analysis systems, has been designing, manufacturing and marketing high performance analyzers for laboratories and hospitals for over 30 years. This expertise that has made the company one of the world leaders in Hematology and a key player in the Hemostasis and Clinical Chemistry activity.

HORIBA Medical and CEA-Leti Strengthen Their Partnership to Develop Tomorrow’s Diagnostics at the Point of Care

Montpellier and Grenoble, France | Posted on July 21st, 2020

Today, patient care and treatment practices are evolving quickly. HORIBA Medical is designing solutions to anticipate patient-centered needs by developing new POCT (Point of Care Testing) systems.



In parallel, for the past six years HORIBA Medical has been working with one of the most innovative organizations in the field of new technologies, CEA-Leti, the technology research laboratory of CEA Tech, federating their respective skills in a Joint Laboratory called HEMACOUNT.



“We focused on two disruptive technologies: a microfluidic cartridge and a new, lens-free imaging device (LensFree), which will enable development of more compact, easier-to-use POCT-type devices,” says Damien Isebe, who heads up this highly innovative project at HORIBA Medical. “Twelve families of patents have been filed since the start of the project, and the latest one has been the subject of several scientific papers”.



“Flow cytometry is the main analytical technology in hematology, but it requires large and complex hardware systems. Conversely, lens-free imaging combined with a sample prepared as a microfluidic cartridge paves the way to a simple and compact disruptive architecture. This imaging technique provides a wide field of view (≈30mm˛) resulting in a counting statistic (a few thousand cells) in one single acquisition consistent with required hematological performance,” explains Sophie Morales, laboratory head at CEA-Leti.



The latest publications and presentations to date: for LensFree, one publication in the Journal of Biomedical Optics and two oral presentations at ECBO (European Conferences on Biomedical Optics), held in Munich in late June 2019; and for the work on microfluidics, presentation of a scientific poster at µTAS (International Conference on Miniaturized Systems for Chemistry and Life Sciences) in Basel, Switzerland, in October 2019.



Given the success of the partnership and the work that remains to be done, HORIBA Medical is pleased to announce the continuation of this collaboration, which will allow it to draw value from this work in the form of innovative applications, to bring developments to maturity and to design products that will serve care-givers and patients.



Patents: DD17052- FR1663028: “Procedure for counting particles in a sample by lens-free imaging”

####

About Leti
Leti, a technology research institute at CEA, is a global leader in miniaturization technologies enabling smart, energy-efficient and secure solutions for industry. Founded in 1967, CEA-Leti pioneers micro-& nanotechnologies, tailoring differentiating applicative solutions for global companies, SMEs and startups. CEA-Leti tackles critical challenges in healthcare, energy and digital migration. From sensors to data processing and computing solutions, CEA-Leti’s multidisciplinary teams deliver solid expertise, leveraging world-class pre-industrialization facilities. With a staff of more than 1,900, a portfolio of 3,100 patents, 10,000 sq. meters of cleanroom space and a clear IP policy, the institute is based in Grenoble, France, and has offices in Silicon Valley and Tokyo. CEA-Leti has launched 65 startups and is a member of the Carnot Institutes network. Follow us on www.leti-cea.com and @CEA_Leti.

About HORIBA Medical

HORIBA Medical offers an extensive and comprehensive line of hematology, coagulation and clinical chemistry solutions (including reagents) for in vitro diagnostics. The HORIBA Medical brand has earned the trust of a wide customer base through the quality and reliability of its products. Today, over 30,000 laboratories around the world use HORIBA Medical solution (more information at: www.horiba.com).

For more information, please click here

Contacts:
Press Contact HORIBA Medical

Carole Barascud

Public and Media Relations



Tel. +33.4.67.14.15.59



Press Contact CEA-Leti

Agency

Tel. +33 6 74 93 23 47

Copyright © Leti

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Chemistry

Breaking carbon–hydrogen bonds to make complex molecules November 8th, 2024

Imaging

New material to make next generation of electronics faster and more efficient With the increase of new technology and artificial intelligence, the demand for efficient and powerful semiconductors continues to grow November 8th, 2024

News and information

Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024

Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Possible Futures

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

Nanomedicine

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery: NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery September 13th, 2024

Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024

Nanobody inhibits metastasis of breast tumor cells to lung in mice: “In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.” August 16th, 2024

Discoveries

Breaking carbon–hydrogen bonds to make complex molecules November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

Patents/IP/Tech Transfer/Licensing

Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023

Study finds nanomedicine targeting lymph nodes key to triple negative breast cancer treatment: In mice, nanomedicine can remodel the immune microenvironment in lymph node and tumor tissue for long-term remission and lung tumor elimination in this form of metastasized breast cance May 13th, 2022

Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020

Nanobiotechnology

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery: NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery September 13th, 2024

Nanobody inhibits metastasis of breast tumor cells to lung in mice: “In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.” August 16th, 2024

The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024

Research partnerships

Gene therapy relieves back pain, repairs damaged disc in mice: Study suggests nanocarriers loaded with DNA could replace opioids May 17th, 2024

Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024

Researchers’ approach may protect quantum computers from attacks March 8th, 2024

How surface roughness influences the adhesion of soft materials: Research team discovers universal mechanism that leads to adhesion hysteresis in soft materials March 8th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project